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The salivary glands are tissues at risk during radiotherapeutic
treatment of head and neck tumours. Exposing the salivary glands
to radiation often results in a progressive irreversible loss of gland
function, which may persist during the rest of the patient’s life,
leading to irreversible and distressing oral complaints (Shannon 
et al, 1978; Valdez et al, 1992; Leslie and Dische, 1994). These
consequences of the treatment have a negative impact on the
quality of life of the patients (Jensen et al, 1994). Therefore protec-
tion of the salivary glands against radiation damage is of great
importance. 
The loss of salivary flow may already be observed after a few
fractions of radiation (Shannon et al, 1978). This early response on
gland function has been studied thoroughly in rats (e.g. Vissink 
et al, 1990; Franzén et al, 1991; Nagler et al, 1993; Coppes et al,
1997a, b). Within 3 days after irradiation with a single dose of 15
Gy of X-rays a decrease in salivary flow rate of near 50% can be
observed (Vissink et al, 1990; Peter et al, 1995; Coppes et al,
1997a, b). The literature on radiation-induced changes in
morphology is somewhat contradictory. Observations regarding
loss of gland weight and acinar cells (Phillips, 1970; Sodicoff et al,
1974), the latter being the major sites of fluid production 
(Garrett and Proctor, 1998), stand in contrast to the lack of obvious
quantitative morphological alterations (Franzén et al, 1991;
Henricksson et al, 1994) and the lack of increase in apoptotic cells
(Paardekooper et al, 1998) early after irradiation. The early effects
of radiation on the parotid gland may therefore rather be due to
dysfunctioning of non-removed cells at the level of membranes
(Sodicoff et al, 1974; EI Mofty and Kahn, 1981; Vissink et al,
1992) and/or intracellular signalling (Vissink et al, 1991; Coppes
et al, 1997b). The late effects of radiation on the parotid gland
have been studied less extensively, but can be described by a dose-
dependent further decline in function (Nagler et al, 1998), loss of
acinar cells and the development of fibrosis (Henricksson et al,
1994). Regretfully, in the latter studies the whole or half of the
head including the glands were irradiated. Therefore indirect
effects due to damage to other organs confounds the interpretation
with regards to salivary gland function. No study so far has been
performed studying the early-to-late effects of radiation on parotid
gland function in the same rat. The approach used in this study
provides the means to determine, for the first time, changes in
parotid gland function over a longer period within the same rat. 
Xerostomia is multifactorial depending on changes in salivary
output from all major glands as well as the minor glands (Eisbruch
et al, 1999). Although parotid gland dysfunction does not neces-
sarily lead to xerostomia, it is of great clinical importance to find
drugs that are able to protect against radiation damage to the
glands, especially against late effects. Pilocarpine has been used to
relieve the symptoms of postirradiation xerostomia (Johnson et al,
1993; Leveque et al, 1993). Recently, prophylactic treatments with
pilocarpine and some related drugs have been shown (Peter et al,
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BJOC 01-2038 1055-1063  1/10/01  11:38 am  Page 10551995; Coppes et al, 1997a, b) to protect against the early (0–30
days post irradiation) effects of radiation on rat salivary gland
function. 
Since nothing is known about the duration of the protection,
these studies were extended till 240 days after irradiation in the
current study. For this purpose, we locally irradiated the parotid
glands of the rat with or without pretreatment with adrenergic and
muscarinic receptor agonists consecutively following early-to-late
radiation damage. A single dose of 15 Gy was choosen as earlier
studies (Vissink et al, 1990, Roesink et al, 1999) have shown that a
saturation of the radiation effects occurs at higher doses. Whereas
rapid function loss after irradiation was characterised by a rapid
decline in flow rate without changes in amylase secretion or acinar
cell number, amylase secretion decreased later after radiation in
parallel with a loss of acinar cells. Very late after radiation, the
gland function further deteriorated despite an increase in acinar
cell number that, however, was associated with a poor overall
tissue morphology with some signs of fibrosis. 
We found that whereas pretreatment with most drugs can only
temporarily ameliorate gland function after X-rays, a combination
of the muscarinic receptor agonist methacholine plus the α -adren-
ergic receptor agonist phenylephrine was effective over the whole
follow-up period. 
Information obtained by parallel detection of gland function
(flow rate, amylase secretion), general morphology, cell percent-
ages and gland weight allowed us to postulate a mechanism of the
sequential radiation-induced damage to the parotid gland and
protection against this damage. The latter provides us with tools to
design clinically applicable protocols to ameliorate the short-and
long-term side effects of radiotherapeutic treatment of head and
neck cancer. 
MATERIALS AND METHODS 
Animals 
Young adult (8–9 week old) male albino Wistar rats (strain
Hds/Cpb: WU), weighing approximately 230 g, purchased from
Harlan CPB Rijswijk, The Netherlands, were used in all studies.
They were kept in polycarbonate cages (6 rats per cage) under a
14:10-h light : dark cycle. The rats were housed for 10 days prior
to the experiments. Food (RMH-B, Hope Farms, Woerden, the
Netherlands) and water was given ad libitum. All experiments
were performed in agreement with the Netherlands Experiments
on Animal Act (1977), the European Convention for the Protection
of Vertebrates Used for Experimental Purposes (Strasbourg,
18.III.1986) and met the standards required by the UKCCCR
Guidelines (UKCCR, 1998). 
Parotid gland irradiation 
The rats were irradiated as previously described (Coppes et al,
1997a). Prior to irradiation all rats were anaesthetised by an i.p.
injection of Ketamine (Ketalar, 60 mg kg–1) and Xylazine
(Rompun, 2.5 mg kg–1). A 6 mm lead shield with a portal of
2 × 5 cm was positioned over the body of the rat so that, except for
the parotid/submandibular region, the body, including the oral
cavity, was excluded from the irradiation field (Coppes et al,
1997a). Both glands were irradiated with a single dose of 15 Gy.
The X-ray apparatus (Mueller MG 300, Philips, Eindhoven, The
Netherlands) was operated at 15 mA, 200 kV (filters: 0.5 mm
copper and 0.5 mm aluminium; HVL = 1 mm Cu). The treatment
distance to the focal spot of the skin was 32.5 cm, leading to a dose
rate at the gland level of 1.0 Gy min–1. This dose rate was deter-
mined in air with a calibrated electrometer and ionisation chamber
combination (Keithley 35040+NE-2571). The tissue outside the
primary beam received less than 1% of the dose applied. 
Treatments 
The animals were divided randomly into 7 groups. The sham
group was sham-irradiated and sham-treated (1 ml kg–1 saline, 1 h
prior to sham-irradiation). The control group was sham-
treated prior to irradiation. The other groups were treated before
irradiation, with adrenergic and/or muscarinic acetylcholine
receptor (MAChR) agonists. One group was treated with the α -
adrenergic receptor (α -AR) agonist phenylephrine, 5 mg kg–1, 60
min prior to irradiation. A second group was treated with the β -
adrenergic receptor (β -AR) agonist isoproterenol 5 mg kg–1, 90
min prior to irradiation. A third group was treated with metha-
choline 3.75 mg kg–1, 60 min prior to irradiation. A fourth group
was treated with pilocarpine, 4 mg kg–1, 60 min prior to irradiation
and a fifth group was treated with methacholine, 3.75 mg kg–1 plus
phenylephrine, 5 mg kg–1, 120 and 60 min prior to irradiation,
respectively. The selection of drugs, drug combinations as well as
most dose-schedules originate from the studies to test the degranu-
lation concept (Coppes et al, 1997a, b). In these studies, we found
short-term protection of both non-degranulating and degranulating
drug pre-treatments. The dose schedules were based on obtaining
maximal receptor stimulation. 
Drugs 
Phenylephrine (L-phenylephrine-hydrochloridium, Sigma, St.
Louis, MO), Isoproterenol (dl-isoproterenol-hydrochloride,
Sigma), Methacholine (acetyl-β -methylcholine chloride, Aldrich
Chemical Co., Milwaukee) and Pilocarpine, ((+)-pilocarpine
hydrochloride, University Pharmacy, Groningen, The Nether-
lands), were dissolved in saline and injected i.p. 
Collection of saliva 
For saliva collection experiments in total 56 animals were used, 8
per experimental group. All collections were performed under
anaesthesia. The rats were randomly divided in time for radiation
and sampling. The time between irradiation and the first sampling
at day 1 was between 22–24 hours. The sham rats were also anaes-
thetised to excluded anaesthesia effects on food and water intake
and (subsequent) saliva flow. The rats were anaesthetised by an
i.p. injection of 60 mg kg–1 Brietal® and intubated to minimise
respiratory complications. Saliva samples of both left and right
parotid gland were collected at the same time under
halothane/N2O/O2 anaesthesia by means of miniaturised Lashley
cups (Vissink et al, 1989). The cups were placed upon the orifices
of both parotid glands. Saliva was collected for 30 min after stim-
ulation with 2 mg kg–1 pilocarpine administered subcutaneously
(given at t = 0 and t = 15 min). Parotid saliva secretion was
collected in preweighted ice-cooled plastic tubes. Saliva was
collected 4 days before and 1, 3, 7, 10, 30, 60, 120, 180 and 240
days after irradiation. As a parameter for the assessment of parotid
gland function, saliva flow rates and amylase secretion were deter-
mined. The total volume of saliva secreted was estimated by
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salivary flow rate (µ l min–1) was calculated from the collecting
time (min) and volume of saliva secreted (µ l). Amylase secretion
was determined by multiplying the amylase concentration in the
collected saliva as quantified by the method of Pierre and Nadj
(1976) by the flow rate. The flow rate and amylase secretion was
expressed as % of the value before irradiation (± SEM). 
Morphology 
For histopathology 3 rats were sacrificed for each time point 1, 3,
7, 10, 30, 60, 120, 180 and 240 days after treatment with radiation
alone (27 rats) or after different drug pre-treatment (phenyle-
phrine, pilocarpine, methacholine and methacholine plus phenyle-
phrine) followed by radiation (108 rats). As a control for
age-dependent changes, gland histology was assessed in sham-
treated rats 4 days before, 10, 30, 120, 180 and 240 days (18 rats).
The rats were anaesthetised by an i.p. injection of 60 mg kg–1
sodium pentobarbital (University Pharmacy, Groningen, The
Netherlands). The animals were exsanguinated before the parotid
glands were prepared free from surrounding tissue. Hereafter 
the glands were extirpated. After rinsing with PBS the wet weight
of the glands was determined and subsequently the tissue was
incubated for 24 h at room temperature in a 5% (v/v) solution of
formaldehyde in phosphate buffer, pH 7.4. Following dehydration
using graded alcohol series, the tissue was embedded in Technovit
7100 resin (Heraeus Kulzer GmbH, Wehrheim, Germany) and
using a microtome (Jung, Heidelberg, Germany), 2 µ m sections
were cut. The sections were stained with Haematoxylin (Gill No 2,
Sigma diagnostics, St Louis, MO) and eosin (bluish eosin,
Chroma-Gesellschaft, Koengen, Germany). The sections were
coded and scored in a random order by a certified histologist
(LJWZ), who was blinded for all sections including the treatment
arm. Internal controls for the observer variability were included.
Acinar, intercalated duct and striated duct cells were counted in 5
randomly chosen fields per section (field size: 145 × 215 µ m2 at
600 × magnification). Aberrant nuclei, vacuoles, granulation level
of acinar cells, cell–cell contact, contact between acini, blood
vessels and connective tissue were scored arbitrary by comparing
them to control and non-pretreated irradiated glands. The number
of cells scored in 5 randomly chosen high-power fields per section
were averaged. This value was multiplied by the gland weight of
that rat divided by the average gland weight of unirradiated rats 4
days before treatment. Thus a value in arbitrary units proportional
to the absolute number of cells of that type per gland was obtained.
The number of cells calculated for sham-treated 4 days before
treatment was set to 100%. The values for the other conditions
were then expressed as a percentage (± SEM) of this control. 
Data analysis 
The results are described in intervals. Acute, early, intermediate
and late effects describe the events happening during the first 10
days, 10–60 days, 60–120 days and 120–240 days after irradiation,
respectively. The choice of the intervals is, of course, also depen-
dent on the available points of measurement and therefore neces-
sarily global. As a result also the periods in time that different
forms of damages become manifest, are rough estimations. 
The results were analysed using a 2-sided Student’s t-test for
paired or unpaired data; probabilities below 5% were taken to be
significant. 
RESULTS 
Adverse effects 
No radiation-induced mortality was observed. Out of a total of 56
rats used in the saliva collection experiments, 15 died before the
end of the experimental period during the recovery from anaes-
thesia. This was due to saliva leakage into the bronchus after
removal of the Lashley cups. This occurred without any relation to
the treatment the rats received. This means, however, that with
time after treatments the number of measurements per treatment
group was reduced. However, the variation between the data
within the same group at a certain time point was small enough to
reveal significant inter-treatment differences even at the later time-
points with reduced numbers of animals. At the end of the experi-
ments at least 5 rats per experimental group remained. None of the
rats used for morphology died prematurely. Development of
pseudomembranes or ulcers, known to interfere with the nutri-
tional status, was observed in none of the cases. At 60 days after
irradiation some loss of hair was observed in the irradiated groups
at the position of the radiation portal. The animals weighed 280 ±
3 g at the start of the experiment. The body weight of all irradiated
rats decreased reaching a minimum 6 days after irradiation (about
93% of the original body weight). Examination of the oral cavity
did not reveal any signs of mucositis during the first week of
sampling. From day 10 after irradiation all body weights increased
in parallel with the shams, never completely making up for the
difference. All drugs and combinations of drugs were also tested in
the non-irradiated situation. The drug treatment as such, did not
result in changes in flow rate, amylase secretion or cell numbers
(see Coppes et al, 1997a, b). Drug induced changes in mean arte-
rial blood pressure and heart rate, as measured by the tail-cuff
method, were returned to (near) normal at the time of radiation. 
Up to now, no data are available which in consecution describe
acute-to-late irradiation-induced changes in parotid gland function
and morphology. To establish the effect of 15 Gy of X-rays,
successive measurements of flow rate, amylase secretion,
morphology and number of acinar cells/gland were performed up
to 240 days after irradiation. The results obtained are plotted in
Figure 1, expressed as percentage of values before irradiation.
Prior to irradiation the mean flow rate of all rats was 10.1 ± 0.3 µ l
min–1, the amylase secretion was 78.3 ± 4.9 U min–1, number of
acinar cells per high power field was 4.9 ± 0.2 cells µ m–2, and the
gland weight was 206 ± 14 mg. 
Effects of irradiation on flow rate, amylase secretion,
acinar cell number and tissue morphology 
Flow rate was determined to quantify the capability of the gland to
secrete saliva. As shown in Figure 1, radiation caused a decline in
pilocarpine-induced saliva flow rate. Firstly, a rapid decline is
observed with a minimum already reached at 6 days postirradia-
tion (Figure 1A). Secondly, a significant further deterioration
between 180 and 240 days was found, leading to a secretory level
of 31 ± 5% (P < 0.01) of the control (Figure 1B). 
Amylase secretion was determined to evaluate the quality of the
saliva. Similar to the changes in flow rate, radiation induced a 2-
phased reduction in amylase secretion, but with different kinetics.
No significant decrease in amylase secretion up to 10 days after
irradiation was observed (Figure 1A). This is consistent with
earlier reports (Gustafsson et al, 1992; Peter et al, 1995) but
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radiation effects on amylase secretion may have been caused by an
oropharyngeal syndrome in the animals due to irradiation of the
entire head. The major decline in amylase secretion started
between 10 and 30 days after irradiation reaching a minimum after
60 days (Figure 1B). A second less pronounced decline occurred,
more or less parallel to the flow rate, between 180 (range
17.9–48.9%) and 240 (range 2.8–32.8%) days postirradiation
(P < 0.05). 
Radiation did not induce changes in acinar cell number up to 10
days postirradiation (Figure 1A). From day 10 on, the acinar cell
number decreased in parallel with the amylase secretion (Figure
1B). Immediately after irradiation a decrease in granulation level
and an increase in size and number of vacuoles of the acinar cells
was observed. The number of aberrant nuclei increased but never
exceeded a level of 3% (see also Paardekoper et al, 1998). The
tissue morphology of the gland improved at day 10, although the
number of aberrant nuclei remained elevated up to day 30 after
irradiation. When compared to sham irradiation (Figure 2A) the
contact space between acini, but not between the cells within one
acinus was reduced, suggesting interstitial oedema (Figure 2B). A
slight elevation of fibrotic tissue was observed from day 60 on (not
shown). In contrast to both the flow rate and the amylase secretion,
the number of acinar cells recovered from day 120 postirradiation
on (Figure 1B), accompanied by a second increase in aberrant
nuclei (not shown) and in the number of vacuoles (not shown).
Acini seemed to be enlarged and contained up to 30 acinar cells in
a cross-section, compared to 10 in unirradiated acini (Figure 2C).
The acinar cells within these acini, however, were disorganised
and smaller. At 240 days after irradiation, this effect was more
pronounced and much healthy tissue was replaced by fibrotic areas
(Figure 2D). 
Of the drugs used in this study, pilocarpine was of special
interest, because it is already used in the clinic for the treatment of
radiation therapy-induced xerostomia and salivary dysfunction
(Johnson et al, 1993; Leveque et al, 1993; Valdez et al, 1993). It
was shown earlier (Coppes et al, 1997b) that pilocarpine pretreat-
ment in rats can reduce the acute and early effects of radiation on
the parotid gland flow rate. This is confirmed here (Figure 3 (until
day 60, P < 0.05, n = 7–8) ). Pilocarpine also reduces the acute and
early reduction in amylase secretion (day 30–120, P < 0.05, n =
6–8 as well as the early decline in acinar cell number (day 30–60,
P < 0.01, n = 3). The late effects, however, are not reduced (Figure
3). This urges the need for improved prophylactic treatments. 
Alternative drug pretreatments for early and late
protection 
In a previous study (Coppes et al, 1997a, b), we reported on a
series of drug pretreatments that, like pilocarpine pretreatment,
can attenuate the early radiation-induced decline in parotid gland
function. As can be seen in Figure 4A, pretreatment with isopro-
terenol (ISO, up to day 120, P < 0.05, n = 6), methacholine (MCh,
up to day 30, P < 0.05, n = 7), phenylephrine (PE) as well as a
combination with PE and MCh indeed can attenuate the acute drop
in saliva flow rate after irradiation. From day 10 on, however, the
sparing effects of all pretreatments decreased up to day 60 (Figure
4B). From day 60 on the flow rates of the different experimental
groups began to differ. Whereas the pilocarpine (Figure 3) and
MCh pretreated groups no longer displayed a sparing effect on the
flow rate, the sparing effects of PE, ISO and MCh + PE remained
or even increased (Figure 4B). At 180 days after irradiation the
ISO pretreated group no longer displayed sparing, whereas the PE
(P < 0.05, n = 6) and especially MCh + PE (P < 0.01, n = 6)
pretreated animals could uphold an increased saliva flow rate up to
day 240 after irradiation, when compared to the untreated irradi-
ated animals. So pretreatment with α -adrenergic receptor (α -AR)
or α -AR + muscarinic acetylcholine receptor (MAChR) agonists
led to long-term protection, whereas pretreatment with β -AR or
MAChR agonists alone only transiently could ameliorate radia-
tion-induced loss in flow rate. 
All pretreatments reduced the effect of irradiation on amylase
secretion (Figure 5). This effect was lost at day 240 after pretreat-
ment with isoproterenol, pilocarpine and methacholine. However,
similar to the flow rate pretreatment with PE/PE + MCh, being α -
AR +/– MAChR agonists, lead to long-term sparing of amylase
secretion (P < 0.001, n = 5 and P < 0.001, n = 7, respectively). 
Neither in non-pretreated nor in drug pretreated rats significant
cell loss was observed up to 10 days after irradiation. However,
formation of vacuoles (Vissink et al, 1990; Peter et al, 1994a) was
seen in non-pretreated but not in the drug pretreated rats (data not
shown) 
At day 30, the acinar cell number in the non-pretreated irradi-
ated rats started to decline (Figure 1B, Figure 6). Except for
methacholine plus phenylephrine, all pretreatments reduced the
rate of cell loss (P < 0.05, n = 3). 
The decline in cell number was less, whereas the numbers 
of aberrant nuclei were higher in drug-pretreated rats, when
compared to the non-pretreated irradiated rats. This effect was
most prominent after pilocarpine (Figure 3) and methacholine
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Figure 1 Changes in parotid gland flow rate (circles), amylase secretion
(squares) and acinar cell number (diamonds) following local irradiation with
15 Gy of X-rays, as a function of time after treatment. The number of acinar
cells are calculated as the number of cells counted multiplied by the ratio of
the gland weight of the experimental rat and the average gland weight of
age-matched control rats. Data are expressed as a percentage of pre-
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BJOC 01-2038 1055-1063  1/10/01  11:38 am  Page 1058pretreatment but only marginal after methacholine plus phenyle-
phrine pretreatment (Figure 6), possibly indicative of drug-
induced delayed cell death. Beyond day 120 only in the
methacholine plus phenylephrine pretreated group acinar cell
numbers were still significantly higher than non-pretreated irradi-
ated rats (Figure 6, P < 0.001, n = 3), whereas the number of aber-
rant nuclei were similar. 
At day 240 after irradiation, the methacholine plus phenyle-
phrine pretreated group displayed less fibrosis and a better but not
normal structure of the acini than non-pretreated group (Figure 2E).
The phenylephrine pretreated group showed intermediate morpho-
logical damage (not shown) and loss of cell number. All other
drugs, including pilocarpine (Figure 2F) lost their protective
effects both on number of cells as well as on morphology. 
Table 1 summarises the effects of pretreatment with adrenergic and
muscarinic agonists on the radiation-induced damage on flow rate. A
composition is made from areas under the curve data, obtained from
flow rate experiments from current (phenylephrine, isoproterenol,
methacholine, pilocarpine and methacholine plus phenylephrine) and
previous (methacholine plus isoproterenol and phenylephrine plus
Sparing of radiation damage to the parotid gland 1059
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Figure 2 Irradiation-induced damage to parotid gland tissue morphology. (A) Parotid gland from non-irradiation animals (Ac) acinar cells, (SD) striated duct
cells and (ID) intercalated duct cells; (B) gland from a non-pretreated animal 10 days after irradiation with 15 Gy of X-rays: occurrence of interstitial oedema
(→ ); (C) gland from a non-pretreated animal 120 days after 15 Gy of X-rays, showing large acini (*) and fibrosis (+); (D) gland from a non-pretreated animal 240
days after irradiation, showing large areas with fibrosis (+); (E) gland from a methacholine plus phenylephrine pretreated animal 240 days after irradiation,
showing preserved general morphology with large acini (*); (F) gland from a pilocarpine-pre-treated animal 240 days after irradiation, showing a near to a similar
picture as glands from irradiated non-pre-treated animals (D) with large acini (*) and fibrosis (+) (H&E, bars: 10 µ m) 
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BJOC 01-2038 1055-1063  1/10/01  11:38 am  Page 1059isoproterenol (Coppes et al, 1997a) ) studies. All single applicated
drugs attenuated the loss of salivary gland function after irradiation
during the acute (0–10 days) and early (10–30 days) periods. The
order of potency in which the different drugs spared saliva flow rate
in the acute and early period is as follows: PILO ≥ MCh ≥ MCh + PE
> ISO > PE. This indicates that stimulation of MAChRs prior to irra-
diation renders the best sparing properties during this time span.
Combining MAChR + β -AR or α -AR + β -AR stimulation showed no
protection at all. In the intermediate period (30–120 days) attenuation
of salivary gland function by pilocarpine, methacholine and isopro-
terenol is almost lost. During the late period (120–240 days) only the
combined methacholine plus phenylephrine and to a lesser degree
phenylephrine alone uphold its sparing effect. During the late period
the order of potency by the drugs used is as follows: MCh + PE > PE
> ISO >> PILO = MCh. This indicates that for long-term sparing
stimulation by α -AR agonists, especially combined with MAChR
agonists renders the best sparing effects, whereas MAChR stimula-
tion alone is ineffective. 
DISCUSSION 
Salivary gland tissue is at risk during radiotherapy of head and
neck cancer. The data presented here are the first to show the
consecutive effects on radiation damage to the parotid gland and
reveal that these effects may be divided into at least 4 distinct
phases. These phases are differentially affected by the irradiation
treatment. Also, the degree of sparing by pretreatments with
muscarinic and/or adrenergic receptor agonists differs in extent
and duration. Previously, it has been shown (Peter et al, 1995;
Coppes et al, 1997a, b) that the early effects of radiation damage to
these glands can be attenuated by pre-irradiation treatment with
adrenergic and/or muscarinic receptor agonists. This includes the
clinically applied drug pilocarpine. Our current data show that the
latter drug is unable to protect against the long-term effects of a 15
Gy irradiation treatment when 100% of the parotid gland lies
within the radiation portal. Most importantly, our results indicate a
novel approach to ameliorate both early and late radiation effects
on the parotid glands based on simultaneous pre-irradiation stimu-
lation of muscarinic and α -adrenergic receptors. These effects
were accomplished with non-clinically applicable drugs.
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Figure 3 Effects of pilocarpine pretreatment on changes in parotid gland
flow rate (circles), amylase secretion (squares) and acinar cell number
(diamonds) following local irradiation with 15 Gy of X-rays after pilocarpine
pre-treatment. (A) Acute effects, 0–10 days after radiation. (B) Early to late
effects, up to 240 days days after irradiation. Open symbols indicate the flow
rates for non-pretreated animals following 15 Gy. The number of acinar cells
are calculated as the number of cells counted multiplied by the ratio of the
gland weight of the experimental rat and the average gland weight of
age-matched control rats. Data are expressed as a percentage of
pre-treatment control values and are the mean values (± SEM)
no rad
no drug
PEs
ISO
MCh
MCh+PE
Time (days) after 15 Gy of X-rays
F
l
o
w
 
r
a
t
e
 
(
%
 
o
f
 
c
o
n
t
r
o
l
)
120 0 30 60 90 150 180 210 240 0
25
20
50
75
100
B
05 1 0
0
50
40
75
100
Time (days) after 15 Gy of X-rays
F
l
o
w
 
r
a
t
e
 
(
%
 
o
f
 
c
o
n
t
r
o
l
)
A
Figure 4 Effect of drug pretreatments on changes in parotid gland flow rate
following irradiation with 15 Gy of X-rays. (A) Acute effects, 0–10 days after
radiation. (B) Early to late effects, up to 240 days after irradiation. No rad:
Not pretreated, no irradiation; No drug: saline pre-treated. PE: phenylephrine,
ISO: isoproterenol, MCh: methacholine, MChPE: methacholine plus
phenylephrine. Data are expressed as a percentage of pretreatment control
values and are the mean values (± SEM) 
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Figure 5 Effect of drug pretreatments on changes in parotid gland amylase
secretion following irradiation with 15 Gy of X-rays. No rad: not pre-treated,
no irradiation; No drug: saline pre-treated. PE: phenylephrine, ISO:
isoproterenol, MCh: methacholine, MChPE: methacholine plus
phenylephrine. Data are expressed as a percentage of pre-treatment control
values and are the mean values (± SEM) 
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there relation to effective drug pretreatments, might help to design
clinically applicable long-term protectors of radiation damage to
the parotid gland. 
Damage initiation and target cells 
The degree of radiation damage inflicted to organs as well as the
time of manifestation of the damage depend on the type and
number of target cells involved. Saliva is firstly formed by acini as
an isotonic primary secretion, which is then rendered hypotonic by
the removal of sodium and chloride as it flows through the ductal
system with little or no change in fluid volume (Garrett and
Proctor, 1998). Therefore, acinar cells may be considered as
primary target cells, which when damaged to their secretory poten-
tial or when disappeared (after cell killing), have an immediate
effect on salivary secretion. Although not fully established, it
seems (Budford-Mason et al, 1993; Redman, 1995; Denny et al,
1997; Dardick, 1998) that at least 2 types of acinar cells exist, cells
capable of (some) division and end-stage cells. It is not clear
whether or not these cells have equal secretion abilities. Radiation
damage to acinar cells may therefore have different effects namely
on secretion and on cell renewal. Dividing acinar cells may be
considered primary as well as secondary target cells dependent on
the type of damage manifested in these cells. Cell renewal, espe-
cially after irradiation (Peter et al, 1994b), may also be accom-
plished by division of intercalated duct cells. These cells may
produce new acinar cells and as such be considered as tertiary
target cells. In this view the primary target cells are responsible for
the immediate loss of secretion capacity, the secondary target cells
for impairment of acute cell renewal and the tertiary target cells for
impairment of later cell renewal. How these target cells cope with
the interaction with radiation depends, among other factors, on the
physiological status of the cells. By pretreatment (e.g. by drugs)
this status can be modified such that the cell is conditioned to
better withstand the damaging action of radiation. 
Different phases of radiation damage and cell
regeneration; effects of drug pretreatment 
Acute damage (0–10 days) 
Interaction of radiation with parotid gland tissue immediately
leads to an impaired saliva secretion, without loss of cell number.
The primary target cells are damaged in their potential to secrete
water but not in their potential to secrete amylase. The first
mentioned cellular function is mainly connected with the activa-
tion of the α 1-adrenergic receptor (α 1-AR) and the M3-muscarinic
receptor (M3-AchR) and the interaction with Gq-proteins (Sawaki
et al, 1995), while secretion of proteins depends on β -adrenergic
receptor (β -AR) activity and the interaction with Gs-proteins
(Gomperts, 1990). We may not conclude, however, that radiation
only damages the α 1-AR and M3-AChR signalling pathways and
not the β -AR ones because it may very well be that overcapacity of
the latter pathway compensates for the damage. Pretreatments with
α 1-AR, β -AR and M3-AchR agonists protect the cells against func-
tion loss (Table 1). So the cells are conditioned by the pretreatment
in such a way that they have become radioresistant. It is interesting
to note that isoproterenol (β -AR agonist) protects against loss of
α 1-AR and M3-AchR activities. Although not understood at the
moment, it points to interactions between the different signalling
pathways. The most interesting observation with respect to acute
radiation damage is the phenomenon of non-protection when
pretreatment with a β -AR agonist is coupled with pretreatment
Sparing of radiation damage to the parotid gland 1061
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Figure 6 Effect of drug pretreatments on changes in parotid gland acinar
cell number following irradiation with 15 Gy of X-rays. No rad: not pre-treated,
no irradiation; No drug: saline pre-treated. PE: phenylephrine, MCh:
methacholine, MChPE: methacholine plus phenylephrine. The number of
acinar cells are calculated as the number of cells counted multiplied by the
ratio of the gland weight of the experimental rat and the average gland weight
of age-matched control rats. Data are expressed as a percentage of pre-
treatment control values and are the mean values (± SEM) 
Table 1 Sparing effect by drug pre-treatment on the radiation induced damage to parotid gland flow rate. The follow up time is
split into 4 periods: Acute (0–10 days), Early (10–60 days), Intermediate (60–120 days) and Late (120–240 days). The arrows
indicate the sparing effect as derived from the flow rates experiments 
Drug Receptor Second messenger Acute  Early Intermediate Late 
Phenylephrine α 1-AR PLC/PIP2 ↑ ↑ ↑↑ ↑ ↑ ↑
Isoproterenol β 1-AR AC/CAMP ↑↑ ↑↑ ↑ ↑ ••
Pilocarpine Μ 3 -AchR PLC/PIP2 ↑↑↑ ↑ ↑↑ ↑ ↑ ••
Methacholine Μ 3 -AchR PLC/PIP2 ↑ ↑↑ ↑↑ •• ••
Methacholine + Μ 3 -AchR PLC/PIP2
Phenylephrine + α 1-AR PLC/PIP2 ↑↑ ↑ ↑↑ ↑ ↑↑ ↑↑
Methacholine + Μ 3 -AchR PLC/PIP2 •• •• nd nd
Isoproterenol + β -AR AC/cAMP
Phenylephrine + α 1 -AR PLC/PIP2 •• •• nd nd
Isoproterenol + β -AR AC/cAMP
•• no effect, ↑ and ↑ about 25% and 12.5% protection, respectively, nd not determined.
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This is likely due to mutual inhibition between the PLC/PIP2 and
AC/cAMP second messenger pathways (Fleming et al, 1992;
Gerstin and Ehlert, 1996; Martinez and Zhang, 1998). When we
accept the hypothesis of temporarily cell conditioning by the
pretreatment then we have to conclude that the combined β -
AR/α 1-AR-M3-AchR receptor activation prevents this metabolic
conditioning. This cross-talk of signal transduction pathways in
acinar cells is probably connected with phosphorylation reactions
by cAMP/PKA on the muscarinic receptor-Gq protein system
(Chang et al, 1996; Gerstin and Ehlert, 1996; Martinez and Zhang,
1998) and of PKC on the β -adrenergic-Gs protein system (Fleming
et al, 1992; Chang et al, 1996). If this is true, cell conditioning
leading to radioresistance might be caused by receptor activated
(de)phosphorylation reactions on the coupled receptor–G protein
system. So, acinar cells are considered as the primary target cells
for acute radiation damage with the signal transduction pathways
being the targets within these cells. 
Early damage (10–60 days) 
While amylase secretion as well as the number of acinar cells did
not change in the first period, both parameters decreased (Figure
1B) during the second period. The flow rate stayed constant at
about 50% of the level of the non-irradiated gland. This suggests
that between 10 and 60 days the acutely damaged cells were disap-
pearing. There is no compensation of cells by dividing acinar cells,
indicating radiation damage to the secondary targets too. All
agents used protected (more or less to the same extent) against
function loss during this period (Figure 2B, Table 1). The drugs
used also protected against the reduction in amylase secretion and
cell loss, although not all equally effective. This suggests that the
drugs protect against both targets, being the receptor-effector
signalling system leading to improved secretion and the molecular
targets critical for improved cell survival and/or accelerated prolif-
eration resulting in improved tissue renewal after irradiation. 
Intermediate damage (60–120 days) 
In the period of 2 to 4 months after irradiation the damage expressed
in terms of water and protein secretion as well as in terms of cell
numbers is constant, when no pretreatment has taken place.
Depending on the drugs used protection on flow rate is evident. The
best protection (50%) is seen by the combination of methacholine
plus phenylephrine. Methacholine alone does not protect at all.
Furthermore, the protection against cell loss is much lower as seen
from the combination with phenylephrine. Noteworthy is the relative
low protection in this period by pilocarpine pretreatment. Differences
between the protection against damage to the signalling pathway and
the targets for cell killing become manifest. 
Late damage (120–240 days) 
From a clinical perspective, this is the most important period
studied. The amount of acinar cells increased (Figure 1B and
Figure 6). Part of the increase may be explained by normal growth
(see control, Figure 6) the other part may be considered as a
response to radiation and the result of tissue replenishment via
dividing acinar cells and cells of the intercalated duct. Despite the
increase in cell number, the function of the gland deteriorates
during this period to about 30% of the nonirradiated situation,
which is consistent with previous observations by others
(Funegard et al, 1997; Nagler et al, 1998). This probably relates to
the abnormal morphology of the (large) acini observed at this time
point (Figure 2D). The loss of flow rate can only be protected by
pretreatment with phenylephrine but more effectively in combina-
tion with methacholine (Figure 4B, Table 1). The protection by
these drugs is also evident for amylase secretion, number of cells,
and tissue morphology. Our data could suggest that the combina-
tion of α -AR and MAChR stimulation by phenylephrine and
methacholine, respectively, exerts an effect on the intercalated
duct cells (tertiary target cells), necessary for long-term repopula-
tion (Budford-Mason et al, 1993; Redman, 1995; Denny et al,
1997; Dardick, 1998). 
Unfortunately, the drugs used in the current study cannot be used
clinically in the concentration necessary to exert their effect. Yet, for
the first time this study shows that the salivary gland can be
protected against late radiation damage by pretreatment of receptors
agonists, which have been shown to activate separately the
PLC/PIP2 second messenger pathways (Sawaki et al, 1995), indi-
cating possible involvement of these 2 second messenger pathways. 
This finding opens the way for searching clinically applicable
drugs that lead to cell conditioning by the same mechanism but
with less toxic side effects as compared to the drugs used in the
current study. This type of work is now ongoing in our laboratory. 
In summary, the data show that radiation damage to the parotid
gland can be described as 4 phases in time, firstly a rapid loss 
of function occurring without cell loss, followed by a phase of loss of
acinar cells, hereafter a steady state phase, and finally a further
deterioration of gland function and morphology, albeit with an
increase in number of (abnormally arranged and probably nonfunc-
tional) acinar cells. All drug pretreatments reduced the damage to
the first 2 phases but only a combined stimulation of muscarinic
acetylcholine receptors with methacholine plus α -adrenoceptors
with phenylephrine can reduce both early and late damage. 
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